ContraVir Pharma (CTRV) Announces 1-for-70 Reverse Stock Split
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split
May 31, 2019 8:00 AM EDTEDISON, N.J., May 31, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (Nasdaq:Â CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, announced today a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 70 effective May 31, 2019 (the Effective Date). The Companys common stock will begin trading on a split-adjusted basis when the markets open on June 3, 2019 under the existing trading symbol CTRV.
The reverse stock split is primarily intended to bring the Company into compliance... More
